Results 81 to 88 of about 131 (88)

Clinical Safety of Tetravalent Dengue Vaccine, TAK-003, Among Participants With and Without Prior Flavivirus Vaccine Exposure

2023
Escudero, Ian, Shibadas Biswal, Rauscher, Martina, Pang, Hang, Suely Tuboi, Lloyd, Eric, Tricou, Vianney, Folschweiller, Nicolas, Patel, Sanjay S   +8 more
openaire   +1 more source

EE288 Assessing the Value of Dengue Vaccine TAK 003: A Cost-Effectiveness Study in Malaysia

Value in Health
A Azzeri, H Jaafar, R Ting, J Langer, M Dahlui   +4 more
openaire   +1 more source

Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America

Journal of Infectious Diseases
Lulu Bravo, Ana Lúcia Lyrio De Oliveira, Vianney Tricou   +2 more
exaly  

Adverse Events and Immunization Errors Following a Mass Immunization Campaignwith TAK‐003 in Dourados, Brazil: A Post‐Marketing Safety Surveillance Analysis

Journal of Medical Virology
Renato De Ávila Kfouri, Roberto Dias De Oliveira, Julio Croda   +2 more
exaly  

Informe sobre vacunas para dengue con foco en TAK-003 (Qdenga) Actualización 2025.

Marín, Gustavo H, Anahí Álvarez-Rotondo, Cañás, Martin, Urtasun, Martin A   +3 more
openaire   +1 more source

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet Global Health
Delia Yu, Charissa Borja-Tabora, Lulu Bravo   +2 more
exaly  

TAK-003 Dengue Tetravalent Vaccine: An Integrated Safety Analysis by a Combination of Baseline Dengue Serostatus and Sex

Patel, Sanjay S., Rauscher, Martina, Pang, Hang   +2 more
openaire   +1 more source

AVANÇOS E DESAFIOS NA VACINAÇÃO CONTRA A DENGUE: UMA REVISÃO SOBRE CYD-TDV E TAK-003

Anais do Congresso Zarns Interligas
Vanessa Lara Cardoso, RENNAN MIRANDA TAVARES, Larissa Geovanna Nery Gratao   +2 more
openaire   +1 more source